Fig. 2
Kaplan–Meier survival analysis of PSA immunoreactivity (a, b) and a combinatory immunoreactivity score for PSA and Ki67 (c–f) in relation to cancer-specific survival of patients diagnosed at transurethral resection of the prostate and managed by watchful waiting. a, c, e All patients in the cohort and b, d, f Patients diagnosed with Gleason score <7 6 tumors. PSA immune reactivity (IR) was dichotomized by the median value 9 as high (score = 12) or low (<12). Ki67 was dichotomized by cut-off value for the median (c, d) as Ki67 median-high (Ki67 med-high ≥ 2.7%) or Ki67 med-low (<2.7%) or for the highest quartile (e, f) as Ki67 quartile 4-high (Ki67 Q4-high ≥ 5.4%) or Ki67 Q4-low (<5.4%)
